Cognition Therapeutics Presents Promising Zervimesine Phase 2 Study Results

Cognition Therapeutics will present data from its Phase 2 "SHIMMER" study of zervimesine in dementia with Lewy bodies at the Alzheimer's Association International Conference. Results show zervimesine-treated participants had significant improvements in behavioral outcomes, activities of daily living, cognitive fluctuations, and motor symptoms compared to placebo. The study's lead investigator believes zervimesine has great potential in treating DLB symptoms.

Cognition Therapeutics, Inc. is set to present data from its Phase 2 "SHIMMER" study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference (AAIC). The study, directed by James E. Galvin, MD, MPH, and conducted in collaboration with the Lewy Body Dementia Association (LBDA), enrolled 130 adults with mild-to-moderate DLB, who were randomized to receive either daily oral doses of zervimesine (100 mg or 300 mg) or placebo for six months [1].

The study showed significant improvements in behavioral outcomes, activities of daily living, cognitive fluctuations, and motor symptoms among zervimesine-treated participants compared to placebo. Specifically, participants treated with zervimesine tested 86% better on behavioral outcomes (NPI 12), 52% on activities of daily living, 91% on cognitive fluctuations, and 62% on motor symptoms compared to placebo [2].

Dr. Galvin, the lead investigator, expressed optimism about zervimesine's potential in treating DLB symptoms. "The results of the Phase 2 SHIMMER study give hope to the millions of people living with DLB and their healthcare teams, who struggle to treat this complex disease," he stated. "My colleagues and I believe that there is great potential in a once-daily oral medication that slows disease progress while simultaneously reducing the severity and frequency of some of the most troublesome symptoms of DLB."

DLB is the second most common cause of dementia, affecting approximately 1.4 million Americans. Currently, no disease-modifying therapeutics are approved for DLB. The SHIMMER study was supported by a grant award from the National Institute on Aging of the National Institutes of Health (NIH) totaling approximately $30 million [1].

Cognition Therapeutics will present clinical efficacy results and new proteomic findings from both the SHIMMER and SHINE studies at AAIC. The SHINE study, which enrolled 153 adults with mild-to-moderate Alzheimer’s disease, showed that zervimesine treatment preserved cognitive and functional abilities better than placebo in participants with lower levels of p-Tau217 [2].

The SHIMMER study's results, along with the SHINE study's findings, suggest that zervimesine has broad neuroprotective properties. This is particularly encouraging for investors and financial professionals, as it indicates the potential for zervimesine to slow the progression of DLB and improve the lives of those suffering from this complex disease.

References:

[1] https://www.marketscreener.com/quote/stock/COGNITION-THERAPEUTICS-IN-127926318/news/Cognition-Therapeutics-Inc-Announces-Positive-Clinical-Data-from-Zervimesine-Phase-2-Study-in-Deme-50525294/

[2] https://www.biospace.com/press-releases/cognition-therapeutics-positive-clinical-data-from-zervimesine-ct1812-phase-2-study-in-dementia-with-lewy-bodies-dlb-will-be-presented-in-a-podium-presentation-at-aaic